Chênh lệch tiền lương tại Đồng bằng sông Cửu Long dưới góc độ tiếp cận về giới tính và khu vực thành thị - nông thôn

This study analyzes the wage differential of male and female workers, and labor in urban and rural areas in the Mekong Delta provinces using the VHLSS 2014 data. The results of the decomposition of the wage disparity between men and women show unexplained difference has the major contribution in the wage gap between men and women, in particular the differences in the returns to academic and professional degrees for male and female workers. Meanwhile, the explained difference has lower explanatory power, suggesting that most of attributes of male and female labor do not significantly differ. The results of the decomposition of urban-rural wage differential show the opposite: the difference is mainly due to the fact that urban workers are more educated than rural labor, while the unexplained difference has lower explanatory power. Based on these results, the paper proposes a number of recommendations to reduce the income gap in the Mekong Delta

Safety and efficacy of fluoxetine on functional outcome after acute stroke (AFFINITY): a randomised, double-blind, placebo-controlled trial

Background Trials of fluoxetine for recovery after stroke report conflicting results. The Assessment oF FluoxetINe In sTroke recoverY (AFFINITY) trial aimed to show if daily oral fluoxetine for 6 months after stroke improves functional outcome in an ethnically diverse population. Methods AFFINITY was a randomised, parallel-group, double-blind, placebo-controlled trial done in 43 hospital stroke units in Australia (n=29), New Zealand (four), and Vietnam (ten). Eligible patients were adults (aged ≥18 years) with a clinical diagnosis of acute stroke in the previous 2–15 days, brain imaging consistent with ischaemic or haemorrhagic stroke, and a persisting neurological deficit that produced a modified Rankin Scale (mRS) score of 1 or more. Patients were randomly assigned 1:1 via a web-based system using a minimisation algorithm to once daily, oral fluoxetine 20 mg capsules or matching placebo for 6 months. Patients, carers, investigators, and outcome assessors were masked to the treatment allocation. The primary outcome was functional status, measured by the mRS, at 6 months. The primary analysis was an ordinal logistic regression of the mRS at 6 months, adjusted for minimisation variables. Primary and safety analyses were done according to the patient's treatment allocation. The trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12611000774921. Findings Between Jan 11, 2013, and June 30, 2019, 1280 patients were recruited in Australia (n=532), New Zealand (n=42), and Vietnam (n=706), of whom 642 were randomly assigned to fluoxetine and 638 were randomly assigned to placebo. Mean duration of trial treatment was 167 days (SD 48·1). At 6 months, mRS data were available in 624 (97%) patients in the fluoxetine group and 632 (99%) in the placebo group. The distribution of mRS categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio 0·94, 95% CI 0·76–1·15; p=0·53). Compared with patients in the placebo group, patients in the fluoxetine group had more falls (20 [3%] vs seven [1%]; p=0·018), bone fractures (19 [3%] vs six [1%]; p=0·014), and epileptic seizures (ten [2%] vs two [<1%]; p=0·038) at 6 months. Interpretation Oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and epileptic seizures. These results do not support the use of fluoxetine to improve functional outcome after stroke

Effects of Green Supply Chain Management Practices on Sustainability Performance: A Systematic Literature Review and Directions for Future Research

In the context that the world is increasingly paying attention to sustainable development, green supply chain management becomes the optimal solution to help balance the three effects of sustainability: economic, environmental, and social. This paper provides a research overview of sustainability performance and green supply chain management practices. Thence, the authors propose a research model on the impact of green supply chain management on the sustainability performance of small and medium enterprises in Vietnam. Keywords:Green Supply Chain Management (GSCM), sustainability performance, Small and Medium Enterprises. DOI: 10.7176/JESD/13-10-01 Publication date:May 31st 202

Design of Silicon TE0/TE1 Mode Router Using Mach-Zehnder and Multimode Interferometers

This paper proposes a new design of two-mode three-port optical mode router for mode division multiplexing systems. The device consists of a Mach-Zehnder interferometer (MZI) and a multimode interferometer (MMI), which utilizes silicon material for photonic integrated circuits (PIC). By setting appropriate values for the two butterfly-shaped phase shifters (PSs) at MZI and MMI, the input mode, either transverse electric (TE) modes TE0 or TE1, can be routed to the desired output among the three output ports. The device is designed and optimized via three-dimensional beam propagation method (3D BPM). The proposed device achieves very low insertion loss and small cross-talk, which are less than 0.4 dB and -24.5 dB, respectively, over the whole C band

Twelve-Month Outcomes of the AFFINITY Trial of Fluoxetine for Functional Recovery After Acute Stroke: AFFINITY Trial Steering Committee on Behalf of the AFFINITY Trial Collaboration

Background and Purpose: The AFFINITY trial (Assessment of Fluoxetine in Stroke Recovery) reported that oral fluoxetine 20 mg daily for 6 months after acute stroke did not improve functional outcome and increased the risk of falls, bone fractures, and seizures. After trial medication was ceased at 6 months, survivors were followed to 12 months post-randomization. This preplanned secondary analysis aimed to determine any sustained or delayed effects of fluoxetine at 12 months post-randomization. Methods: AFFINITY was a randomized, parallel-group, double-blind, placebo-controlled trial in adults (n=1280) with a clinical diagnosis of stroke in the previous 2 to 15 days and persisting neurological deficit who were recruited at 43 hospital stroke units in Australia (n=29), New Zealand (4), and Vietnam (10) between 2013 and 2019. Participants were randomized to oral fluoxetine 20 mg once daily (n=642) or matching placebo (n=638) for 6 months and followed until 12 months after randomization. The primary outcome was function, measured by the modified Rankin Scale, at 6 months. Secondary outcomes for these analyses included measures of the modified Rankin Scale, mood, cognition, overall health status, fatigue, health-related quality of life, and safety at 12 months. Results: Adherence to trial medication was for a mean 167 (SD 48) days and similar between randomized groups. At 12 months, the distribution of modified Rankin Scale categories was similar in the fluoxetine and placebo groups (adjusted common odds ratio, 0.93 [95% CI, 0.76–1.14]; P =0.46). Compared with placebo, patients allocated fluoxetine had fewer recurrent ischemic strokes (14 [2.18%] versus 29 [4.55%]; P =0.02), and no longer had significantly more falls (27 [4.21%] versus 15 [2.35%]; P =0.08), bone fractures (23 [3.58%] versus 11 [1.72%]; P =0.05), or seizures (11 [1.71%] versus 8 [1.25%]; P =0.64) at 12 months. Conclusions: Fluoxetine 20 mg daily for 6 months after acute stroke had no delayed or sustained effect on functional outcome, falls, bone fractures, or seizures at 12 months poststroke. The lower rate of recurrent ischemic stroke in the fluoxetine group is most likely a chance finding. REGISTRATION: URL: http://www.anzctr.org.au/ ; Unique identifier: ACTRN12611000774921